Report
Julien Onillon
EUR 250.00 For Business Accounts Only

Eurobio Scientific: Mutations that perpetuate value

As expected, the first distributor to market a Covid-19 test in France reported exceptional turnover. Eurobio doubled its sales in the second half of the year compared to the first half and more than tripled its revenue over the year 2020. The results of the distributor of specialized in vitro diagnostic products should be equally exceptional in 2020. From then on, and as the health crisis is brought under control, they will gradually decline and return to "normal" levels. However, the new normality will have nothing to compare with the pre-crisis situation.

Underlying
Eurobio-Scientific SA

Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.

Provider
LPE Research
LPE Research

LPE Research is a new independent equity research firm offering research on demand to fund managers. 

We believe our independent equity research on demand model dedicated to fund managers is the future, that our disruptive equity research on demand model will save money and addresses fund managers real needs, that fund managers should pay only for the equity research they need and if it creates value for them. And we ambition to become fund managers primary outperformance partner.

Our equity research services on demande services are:
- Stock conviction: independent reports
- Stock checking: on demand financial analysis
- Stock coverage: alert and coverage of specific companies
- Stock ideas (to come): list of investment opportunities

Analysts
Julien Onillon

Other Reports on these Companies
Other Reports from LPE Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch